Beta Bionics, Inc. (BBNX)
SEC filings, financial facts, source resources, and Goglides workspace context for Beta Bionics, Inc..
OpenSearch uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
SEC filings, financial facts, source resources, and Goglides workspace context for Beta Bionics, Inc..
OpenZeta reported 50% Q1 revenue growth, raised 2026 guidance again, and launched Athena by Zeta. The proof gate is organic growth, super-scaled customers, adjusted EBITDA margin, and free cash flow.
OpenQ1 2026 revenue beat, raised revenue guidance, and the first sixth-generation 256-qubit system sale. The proof gate is RPO conversion, organic revenue growth, and adjusted EBITDA loss discipline.
OpenGrab reported Q1 2026 revenue growth, record adjusted EBITDA, and stronger on-demand GMV. The proof gate is adjusted EBITDA, adjusted free cash flow, loan quality, and incentive discipline.
OpenEnphase reported Q1 2026 results and announced an IQ solid-state transformer program for AI data centers. The proof gate is revenue stabilization, battery shipments, non-GAAP gross margin, and IQ SST progress.
OpenA filing-led Datavault AI Q1 2026 earnings thesis focused on recognized revenue, tokenization contracts, cash conversion, losses, liquidity, and dilution risk.
OpenBeta Bionics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Open